Osimertinib for Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Current Evidence
{{output}}
Background: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has demonstrated efficacy across multiple treatment lines for patients with EGFR-mutated non-small cell lung cancer (N... ...
